PA Newcomb

1.8k total citations · 1 hit paper
16 papers, 1.1k citations indexed

About

PA Newcomb is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, PA Newcomb has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Cancer Research and 4 papers in Pathology and Forensic Medicine. Recurrent topics in PA Newcomb's work include Cancer Risks and Factors (5 papers), Global Cancer Incidence and Screening (4 papers) and Genetic factors in colorectal cancer (4 papers). PA Newcomb is often cited by papers focused on Cancer Risks and Factors (5 papers), Global Cancer Incidence and Screening (4 papers) and Genetic factors in colorectal cancer (4 papers). PA Newcomb collaborates with scholars based in United States and South Africa. PA Newcomb's co-authors include Barry E. Storer, Robert G. Norfleet, Pamela M. Marcus, Tanya Surawicz, Paul P. Carbone, John D. Potter, Maolong Tang, C. I. Li, Amy Trentham‐Dietz and Kathi Malone and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Epidemiology Biomarkers & Prevention.

In The Last Decade

PA Newcomb

15 papers receiving 1.1k citations

Hit Papers

Screening Sigmoidoscopy and Colorectal Cancer Mortality 1992 2026 2003 2014 1992 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
PA Newcomb United States 6 1.0k 563 474 192 67 16 1.1k
Esther M. Stoop Netherlands 15 1.1k 1.1× 789 1.4× 452 1.0× 378 2.0× 30 0.4× 26 1.2k
V.E.P.P. Lemmens Netherlands 13 498 0.5× 216 0.4× 153 0.3× 268 1.4× 55 0.8× 27 811
Olga Kantor United States 18 608 0.6× 289 0.5× 234 0.5× 408 2.1× 438 6.5× 69 921
Weidong Kong Canada 11 598 0.6× 213 0.4× 84 0.2× 383 2.0× 145 2.2× 21 964
Bivas Biswas India 15 274 0.3× 428 0.8× 114 0.2× 103 0.5× 97 1.4× 104 712
A.C. Braud France 13 483 0.5× 192 0.3× 81 0.2× 198 1.0× 167 2.5× 23 739
Kathryn Evers United States 16 270 0.3× 166 0.3× 219 0.5× 161 0.8× 253 3.8× 30 738
Mitchel Barry Ireland 16 383 0.4× 229 0.4× 177 0.4× 603 3.1× 474 7.1× 39 1.1k
Jorge Otero Colombia 12 307 0.3× 319 0.6× 78 0.2× 127 0.7× 107 1.6× 41 659
Zachary Burningham United States 8 243 0.2× 349 0.6× 95 0.2× 89 0.5× 63 0.9× 36 617

Countries citing papers authored by PA Newcomb

Since Specialization
Citations

This map shows the geographic impact of PA Newcomb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PA Newcomb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PA Newcomb more than expected).

Fields of papers citing papers by PA Newcomb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by PA Newcomb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PA Newcomb. The network helps show where PA Newcomb may publish in the future.

Co-authorship network of co-authors of PA Newcomb

This figure shows the co-authorship network connecting the top 25 collaborators of PA Newcomb. A scholar is included among the top collaborators of PA Newcomb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PA Newcomb. PA Newcomb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hua, Xinwei, Mario Kratz, & PA Newcomb. (2020). Associations between Post-treatment Inflammatory Biomarkers and Survival among Stage II-III Colorectal Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. 29(3). 691–691.
2.
Harrison, Tabitha A., Patrick Campbell, Steven Gallinger, et al.. (2020). Postmenopausal Hormone Therapy Is Primarily Associated with Reduced Risk of Colorectal Cancer Arising through the Adenoma-Carcinoma Pathway. Cancer Epidemiology Biomarkers & Prevention. 29(3). 693–693. 1 indexed citations
3.
Newcomb, PA, et al.. (2017). Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer Epidemiology Biomarkers & Prevention. 26(3). 438–438. 4 indexed citations
4.
Berkman, Amy M., et al.. (2016). The Association Between Post-Diagnosis Health Behaviors and Quality of Life in Survivors of Ductal Carcinoma In Situ. Cancer Epidemiology Biomarkers & Prevention. 25(3). 563–563. 1 indexed citations
5.
Hua, Xin, et al.. (2016). Pre- and Post-Diagnostic Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Cancer Survival in Seattle Colon Cancer Family Registry. Cancer Epidemiology Biomarkers & Prevention. 25(3). 559–559. 3 indexed citations
6.
Trentham‐Dietz, Amy, et al.. (2014). Collagen Fiber Alignment in Relation to Prognostic Markers for Ductal Carcinoma In Situ of the Breast. Cancer Epidemiology Biomarkers & Prevention. 23(3). 565–565. 1 indexed citations
7.
Newcomb, PA, et al.. (2014). Smoking History in Relation to Survival after a Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers & Prevention. 23(3). 569–570. 1 indexed citations
8.
Andersen, Shaneda Warren, et al.. (2013). Breast cancer susceptibility loci in association with age at menarche, age at natural menopause and the reproductive lifespan. Cancer Epidemiology Biomarkers & Prevention. 22(3). 478–478. 5 indexed citations
9.
Malone, Kathi, et al.. (2011). Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. JNCI Journal of the National Cancer Institute. 103(23). 1752–1760. 20 indexed citations
10.
Antill, Yoland, Aung Ko Win, Penelope M. Webb, et al.. (2011). Factors associated with type I and type II endometrial cancers in women with a germ-line mutation in a mismatch repair gene.. Journal of Clinical Oncology. 29(15_suppl). 1521–1521. 1 indexed citations
11.
Ramchandani, Ritesh, et al.. (2010). Socioeconomic Status and Survival after an invasive Breast Cancer Diagnosis. Cancer Epidemiology Biomarkers & Prevention. 19(3). 892–892. 16 indexed citations
12.
Newcomb, PA, et al.. (2003). Long-Term Efficacy of Sigmoidoscopy in the Reduction of Colorectal Cancer Incidence. JNCI Journal of the National Cancer Institute. 95(8). 622–625. 153 indexed citations
13.
Newcomb, PA, Linda Titus‐Ernstoff, Amy Trentham‐Dietz, et al.. (1999). Lactation in relation to postmenopausal breast cancer. Climacteric. 2(4). 294–294. 4 indexed citations
14.
Newcomb, PA & Paul P. Carbone. (1993). Cancer Treatment and Age: Patient Perspectives. JNCI Journal of the National Cancer Institute. 85(19). 1580–1584. 208 indexed citations
15.
Newcomb, PA, Robert G. Norfleet, Barry E. Storer, Tanya Surawicz, & Pamela M. Marcus. (1992). Screening Sigmoidoscopy and Colorectal Cancer Mortality. JNCI Journal of the National Cancer Institute. 84(20). 1572–1575. 707 indexed citations breakdown →
16.
Mazess, Richard B., Howard S. Barden, Sol Epstein, et al.. (1992). 92103997 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. Maturitas. 15(2). 165–165. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026